Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice hearts at later stages of dystrophy

Full text
Author(s):
Mauricio, Adriana Fogagnolo [1] ; Pereira, Juliano Alves [1] ; Neto, Humberto Santo [1] ; Marques, Maria Julia [1]
Total Authors: 4
Affiliation:
[1] Univ Campinas Unicamp, Inst Biol, Dept Struct & Funct Biol, Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: NUTRITION; v. 32, n. 7-8, p. 855-862, JUL-AUG 2016.
Web of Science Citations: 5
Abstract

Objective: In the present study, we investigated whether omega-3 would be effective against dystrophic cardiomyopathy at later stages (13 and 17 mo) of the disease. Methods: Mdx mice (8 mo old) received omega-3 oil (commercially available fish oil; FDC vitamins; omega-3) for 5 mo. Untreated-mdx mice received mineral oil. Heart and diaphragm muscle were evaluated by morphometric (fibrosis), molecular (western blot, inflammatory markers), biochemical (creatine kinase), and functional (electrocardiogram) analyses. Results: Mdx mice presented elevated plasma levels of cardiac creatine kinase (41.2 U/L in normal x 119.6 U/L in untreated-mdx mice), which were significantly decreased by omega-3 treatment. Heart fibrosis was significantly ameliorated by omega-3 treatment at 17 mo of age (untreated-mdx: 20.8% of fibrosis; omega-3-treated: 15.7% of fibrosis in right ventricle). Omega-3 improved some electrocardiogram parameters. Markers of inflammation (tumor necrosis factor alpha, matrix metalloprotease-9, and tissue inhibitor of metalloprotease 1) in mdx heart were significantly decreased by omega-3 treatment. Omega-3 increased beta-dystroglycan levels in mdx heart and did not affect the levels of the profibrotic transforming growth factor beta. Omega-3 ameliorated the dystrophic diaphragm in almost all of the parameters evaluated (fibrosis, transforming growth factor beta, metalloprotease-9, and tissue inhibitor of metalloprotease 1). Conclusions: The present study suggests that omega-3 may be useful in ameliorating dystrophic cardiomyopathy and diaphragm dystrophy in mdx mice at later stages of the disease, further supporting the use of omega-3 in DMD clinical trials. (C) 2016 Elsevier Inc. All rights reserved. (AU)

FAPESP's process: 12/13577-1 - Biomarkers of cardiomyopathy in dystrophy: a metabolomic study and pharmacological therapy
Grantee:Adriana Fogagnolo Mauricio
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 14/04782-6 - Pre-clinical studies in the mdx mouse: metabolomics, biomarkers and omega-3 therapy
Grantee:Maria Julia Marques
Support type: Regular Research Grants